share_log

Aslan Pharmaceuticals Reports Interim Results From Phase 2 Study Of Eblasakimab In Dupilumab-Experienced Atopic Dermatitis Patients

Aslan Pharmaceuticals Reports Interim Results From Phase 2 Study Of Eblasakimab In Dupilumab-Experienced Atopic Dermatitis Patients

阿斯兰制药报告了Eblasakimab在经历过Dupilumab的特应性皮炎患者中进行Eblasakimab的2期研究的中期结果
Moomoo 24/7 ·  04/22 08:33
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发